Navigation Links
Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
Date:11/17/2009

ROCKVILLE, Md., Nov. 17 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Amex: CUR) today provided a financial and business update for the third quarter ended September 30, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )

For the third quarter of 2009, the Company reported a net loss of $5,096,983, or $0.15 per share, compared with a net loss of $3,177,957 or $0.10 per share, for the comparable 2008 period. The increase was due to a non-cash charge related to a change in accounting for certain warrants, offset in part by reductions in other expense categories. Net loss attributable to common stockholders for the first nine months of 2009 was $7,380,751 or $0.22 per share, compared with $8,410,081, or $0.26 per share, for the comparable period in 2008, resulting from a year to date gain in accounting for warrants, partially offset by increases in non-cash stock-based compensation expense, R&D and legal fees.

Cash, cash equivalents and short-term marketable securities at September 30, 2009 totaled approximately $2.4 million, compared with approximately $4.9 million at December 31, 2008. As of September 30, 2009, the Company estimated that cash on hand would be sufficient to meet its operating needs into the first quarter of 2010, including estimated costs associated with the clinical trials for its ALS programs planned for commencement in the U.S. in 2010.

For the nine months ended September 30, 2009, cash used in operating activities totaled $3,613,084, a decrease of $1,118,358 or 24% compared to the same period in the prior year, primarily attributable to an increase of short term financing by vendors, employees and other service providers and a reduction in spending, particular
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
2. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
3. Cadus Reports Third Quarter 2009 Results
4. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on November 16, 2009
5. Sinovac Reports Unaudited Third Quarter 2009 Financial Results
6. Soligenix Reports Third Quarter 2009 Financial Results
7. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
8. Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
9. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
10. China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates
11. YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015  RegeneRx Biopharmaceuticals, ... announced its U.S. joint venture with G-treeBNT (ReGenTree ... phase 3 clinical trial for the orphan disorder, ... trial for dry eye syndrome (DES) in the ... eye drops, RGN-259/GBT201, this year.  Each of these ...
(Date:4/16/2015)... PHOENIX, AZ (PRWEB) April 16, 2015 ... and makes it easier for research institutions to learn ... collect clinical data. , The timing is ideal since ... on Tuesday. Research Kit is an open-source framework for ... 9. It provides a way for researchers to collect ...
(Date:4/16/2015)... DIEGO , April 16, 2015 Avelas ... dedicated to improving cancer surgeries, announced today that it ... fluorescent cancer illuminator, AVB-620, in women with primary, non-recurrent ... the company also welcomed the addition of Steven ... The open label, dose escalation study will ...
(Date:4/16/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company ... new orphan drug indications, today announced that the ... a clinical trial site for the ongoing, multicenter Phase ... multiforme (GBM), the most common and deadly form of ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5
... Colo., Sept. 4 InVitria,( http://www.invitria.com ... animal free,products that enhance productivity, safety ... the biopharmaceutical, cell culture, life science ... of Cambridge Healthtech,Institute,s 4th Annual "Optimizing ...
... Institutes and The University of North Carolina-Chapel Hill ... in Drug Safety Sciences, RESEARCH TRIANGLE PARK, N.C., ... the University of North Carolina at,Chapel Hill announced they ... will be led by Dr. Paul Watkins, one of ...
... CARLOS, Calif., Sept. 4 SleepQuest has partnered,with ... breathing, to conduct clinical trials of a new ... Apnea from,wherever they are sleeping. The technology is ... used to improve the quality of care for ...
Cached Biology Technology:InVitria Sponsors Cambridge Healthtech's Optimizing Cell Culture Development Conference 2New Hamner-UNC Center for Drug Safety Sciences 2New Hamner-UNC Center for Drug Safety Sciences 3Latest Sleep Disorder Technology Tested With SleepQuest 2
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
(Date:4/6/2015)... Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA ... NXT-ID introduces a new revolutionary method ... surrounds the use of miniature antenna modules for ...
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... issue of Proceedings of the National Academy ... mathematical models to analyze huge amounts of data ... in different ocean habitats and metabolic activity in ... in unprecedented detail how environment influences molecular changes ...
... State University process to pretreat corn-crop waste before ... to be added, cutting the cost of making ... expansion) pretreatment process, developed by Bruce Dale, University ... uses ammonia to make the breakdown of cellulose ...
... According to Professor Demain, the petroleum-based economy in the ... lifecycle. Global oil reserves and new petroleum discoveries will ... It is therefore essential to anticipate and avoid any ... new bioenergy alternatives for the marketplace. In the ...
Cached Biology News:Mixing genomics and geography yields insights into life and environment 2Process can cut the cost of making cellulosic biofuels 2
EML1 (K-16)...
Bovine Coronary Artery Smooth Muscle Cells (BCASMC) (>500,000 cells)...
Bovine Aortic Smooth Muscle Cells (BAOSMC) (>500,000 cells)...
... allows the Thermo-Fast® 96 ... PCR plates to be ... PRISM® 3700 capillary sequencer. ... information on the software ...
Biology Products: